Endosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
Open accessThe DOI matches its Crossref record; 43 of the 45 references it cites were found in a registry or an index.
Abstract
The restriction of viral receptors and coreceptors to the basolateral surface of airway epithelial cells has been blamed for the inefficient transfer of viral vectors to the apical surface of this tissue. We now report, however, that differentiated human airway epithelia internalize rAAV type-2 virus efficiently from their apical surfaces, despite the absence of known adeno-associated virus-2 (AAV-2) receptors or coreceptors at these sites. The dramatically lower transduction efficiency of rAAV infection from the apical surface of airway cells appears to result instead from differences in endosomal processing and nuclear trafficking of apically or basolaterally internalized virions. AAV capsid proteins are ubiquitinated after endocytosis, and gene transfer can be significantly enhanced by proteasome or ubiquitin ligase inhibitors. Tripeptide proteasome inhibitors increased persistent rAAV gene delivery from the apical surface >200-fold, to a level nearly equivalent to that achieved with basolateral infection. In vivo application of proteasome inhibitor in mouse lung augmented rAAV gene transfer from undetectable levels to a mean of 10.4 +/- 1.6% of the epithelial cells in large bronchioles. Proteasome inhibitors also increased rAAV-2-mediated gene transfer to the liver tenfold, but they did not affect transduction of skeletal or cardiac muscle. These findings suggest that tissue-specific ubiquitination of viral capsid proteins interferes with rAAV-2 transduction and provides new approaches to circumvent this barrier for gene therapy of diseases such as cystic fibrosis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In vitro and preclinical animal studies have shown administration of bortezomib prevents degradation of internalized AAVs, reduces capsid presentation, and increases transduction efficiency by enhancing nuclear translocation of AAV [165, 224, 225].”
From Immunogenicity of Recombinant Adeno-Associated Virus (AAV) Vectors for Gene Transfer (2023) · cites this paper as [224]
In the citing paper
“After entry into cells, AAV cells can be ubiquitinated for degradation in proteasomes (91), generating increased amount of antigens for immune activation.”
From A versatile toolkit for overcoming AAV immunity (2022) · cites this paper as [91]
In the citing paper
“AAV capsids undergo proteosome-mediated degradation in the cytoplasm, which may expose the packaged genomes to cytoplasmic DNA sensors.”
From Innate immune sensing of adeno-associated virus vectors (2024) · cites this paper as [43]
Citations
Cites
Rock, K. L., Gramm, C., Rothstein, L., Clark, K., Stein, R., Dick, L., Hwang, D., & Goldberg, A. L. (1994) · Cell · doi:10.1016/s0092-8674(94)90462-6 · Cited by 2,524 · cited 1×
“Several specific, cellpermeable, peptide aldehyde inhibitors of proteasome pathways have recently been discovered (30, 31).”
BackgroundFenteany, G., Standaert, R. F., Lane, W. S., Choi, S., Corey, E. J., & Schreiber, S. L. (1995) · Science · doi:10.1126/science.7732382 · Cited by 1,583 · cited 1×
“Several specific, cellpermeable, peptide aldehyde inhibitors of proteasome pathways have recently been discovered (30, 31).”
BackgroundSummerford, C., & Samulski, R. J. (1998) · Journal of Virology · doi:10.1128/jvi.72.2.1438-1445.1998 · Cited by 1,406 · cited 1×
“Recently, the heparin sulfate proteoglycan receptor (3), and FGFR-1 (4) and αVβ5 integrin (5) coreceptors for AAV-2, have been localized to the basolateral membrane of polarized airway epithelial cells (6, 7).”
BackgroundMultiple proteolytic systems, including the proteasome, contribute to CFTR processing
Jensen, T. J., Loo, M. A., Pind, S., Williams, D. B., Goldberg, A. L., & Riordan, J. R. (1995) · Cell · doi:10.1016/0092-8674(95)90241-4 · Cited by 897 · cited 18×
“A similar result was achieved when another ubiquitinproteasome pathway inhibitor, Z-LLL (33), was tested (data not shown).”
BackgroundInfluentialαVβ5 integrin: a co-receptor for adeno-associated virus type 2 infection
Summerford, C., Bartlett, J. S., & Samulski, R. J. (1999) · Nature Medicine · doi:10.1038/4768 · Cited by 711
Fisher, K. J., Gao, G. P., Weitzman, M. D., DeMatteo, R., Burda, J. F., & Wilson, J. M. (1996) · Journal of Virology · doi:10.1128/jvi.70.1.520-532.1996 · Cited by 547 · cited 2×
“Alternative approaches have attempted to increase transgene expression by enhancing the molecular conversion of nonfunctional viral genomes to expressible forms, as in the case of rAAV (12, 13), or by increasing transcription and translation efficiency by altering the transgene expression cassettes (14).”
BackgroundDuan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522 · cited 2×
“It has been previously shown that AAV transduction in certain tissues such as muscle and retina is very efficient (16, 38), whereas other tissues including lung and liver are less favorably transduced (6, 39).”
BackgroundMethodSelf-citationThe Ubiquitin-Proteasome Pathway and Pathogenesis of Human Diseases
Schwartz, P., & Ciechanover, M. (1999) · Annual Review of Medicine · doi:10.1146/annurev.med.50.1.57 · Cited by 466 · cited 2×
“Regulated intracellular proteolysis through proteasomes plays a critical role in many physiological and pathological conditions (35).”
BackgroundSamulski, R. J., Chang, L. S., & Shenk, T. (1987) · Journal of Virology · doi:10.1128/jvi.61.10.3096-3101.1987 · Cited by 449 · cited 1×
“The entire β-galactosidase expression cassette, including the RSV promoter, β-galactosidase reporter gene, and SV40 polyA signal, was excised by Sal I digestion and subsequently cloned into the pSub201 backbone by blunt-end ligation (18).”
MethodHuman fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2
Qing, K., Mah, C., Hansen, J., Zhou, S., Dwarki, V., & Srivastava, A. (1999) · Nature Medicine · doi:10.1038/4758 · Cited by 443
Research works printed but not linked: 3
- Zabner, 1996, Gene Ther, 3, 458
- Hughes, 1993, Lab Invest, 69, 173
- Bennett, 1997, Invest Ophthalmol Vis Sci, 38, 2857
Cited by
Items 101–200 of 389
Ros, C., Burckhardt, C. J., & Kempf, C. (2002) · Journal of Virology · doi:10.1128/jvi.76.24.12634-12645.2002 · Cited by 85
“In these reports, a significant enhancement of recombinant AAV transduction was observed when the proteasome activity was reduced or abolished by a proteasome inhibitor coadministered with the virus.”
BackgroundInfluentialRate Limiting Steps of AAV Transduction and Implications for Human Gene Therapy
Sanlioglu, S., Monick, M., Luleci, G., Hunninghake, G., & Engelhardt, J. (2001) · Current Gene Therapy · doi:10.2174/1566523013348788 · Cited by 85
“Using this same strategy, a dual vector approach was also exploited to augment rAAV mediated gene expression by co-infection with an enhancer carrying vector and promoters or minimal promoter transgene expre-ssing vector (Duan et al., 2000a).”
BackgroundMethodSelf-citationDuan, D., Yan, Z., Yue, Y., Ding, W., & Engelhardt, J. F. (2001) · Journal of Virology · doi:10.1128/jvi.75.16.7662-7671.2001 · Cited by 85
“In our protocol, trypsinization was initially used to confirm that the viral particles were not internalized during the 4°C incubation (10, 13).”
BackgroundMethodInfluentialSelf-citationFerret and Pig Models of Cystic Fibrosis: Prospects and Promise for Gene Therapy
Yan, Z., Stewart, Z. A., Sinn, P. L., Olsen, J. C., Hu, J., McCray, P. B., & Engelhardt, J. F. (2014) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2014.154 · Cited by 88
“The use of proteasome inhibitors during or after infection can dramatically increase apical rAAV transduction of human airway epithelial by enhancing nuclear viral translocation.(41,122)”
Self-citationLi, S., Ling, C., Li, Z., Li, M., Su, Q., He, R., Tang, Q., Greiner, D. L., Shultz, L. D., Brehm, M. A., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.174 · Cited by 83
Shirley, J. L., Keeler, G. D., Sherman, A., Zolotukhin, I., Markusic, D. M., Hoffman, B. E., Morel, L. M., Wallet, M. A., Terhorst, C., & Herzog, R. W. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2019.11.011 · Cited by 79
Yan, Z., Keiser, N. W., Song, Y., Deng, X., Cheng, F., Qiu, J., & Engelhardt, J. F. (2013) · Molecular Therapy · doi:10.1038/mt.2013.92 · Cited by 77
Self-citationEnhancing transduction of the liver by adeno-associated viral vectors
Nathwani, A. C., Cochrane, M., McIntosh, J., Ng, C. Y. C., Zhou, J., Gray, J. T., & Davidoff, A. M. (2009) · Gene Therapy · doi:10.1038/gt.2008.137 · Cited by 77
Expression of Human Factor VIII by Splicing between Dimerized AAV Vectors
Chao, H., Sun, L., Bruce, A., Xiao, X., & Walsh, C. E. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0607 · Cited by 75
Efficient Whole-body Transduction with Trans-splicing Adeno-associated Viral Vectors
Ghosh, A., Yue, Y., Long, C., Bostick, B., & Duan, D. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300153 · Cited by 73
Self-citationDing, W., Yan, Z., Zak, R., Saavedra, M., Rodman, D. M., & Engelhardt, J. F. (2003) · Journal of Virology · doi:10.1128/jvi.77.13.7361-7366.2003 · Cited by 73
“Small tripeptide proteasome inhibitors have been shown to selectively augment long-term transduction efficiencies with rAAV-2 from the apical membrane, but not from the basolateral membrane (5).”
BackgroundSelf-citationLiu, X., Luo, M., Zhang, L. N., Yan, Z., Žák, R., Ding, W., Mansfield, S. G., Mitchell, L. G., & Engelhardt, J. F. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1116 · Cited by 77
“Second, barriers to apical transduction appear to exist for at least two serotypes including rAAV2 and rAAV5 (Duan et al., 1998b, 2000; Bals et al., 1999; Yan et al., 2004).”
BackgroundSelf-citationEnhancing gene delivery of adeno-associated viruses by cell-permeable peptides
Liu, Y., Kim, Y., Ji, M. K., Fang, J., Siriwon, N., Zhang, L. I., & Wang, P. (2014) · Molecular Therapy — Methods & Clinical Development · doi:10.1038/mtm.2013.12 · Cited by 75
Gene therapy for cystic fibrosis
Davies, J. C., Geddes, D. M., & Alton, E. W. F. W. (2001) · The Journal of Gene Medicine · doi:10.1002/jgm.200 · Cited by 70
“Although mechanisms involved in such steps remain incompletely understood, preliminary data with AAV suggest that the use of proteasome inhibitors [40], and endosomolytic peptides [41] may improve gene expression.”
BackgroundGhosh, A., Yue, Y., & Duan, D. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.835 · Cited by 69
“Transgene expression was analyzed at 48 h post-infection by standard cytochemical staining as described [11,20].”
MethodInfluentialSelf-citationCurrent Status of Gene Therapy for Inherited Lung Diseases
Driskell, R. A., & Engelhardt, J. F. (2003) · Annual Review of Physiology · doi:10.1146/annurev.physiol.65.092101.142426 · Cited by 70
“Studies evaluating rAAV transduction biology in the airway suggest that intracellular barriers in polarized airway epithelia also significantly influence the efficiency of transduction from the apical membrane (48).”
BackgroundResultInfluentialSelf-citationThe next step in gene delivery: Molecular engineering of adeno-associated virus serotypes
Wang, J., Faust, S. M., & Rabinowitz, J. E. (2010) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2010.10.017 · Cited by 75
“halves' can be unified by homologous recombination mediated by the ITRs and the splicingmachinery used to generate the correct productive transcript [62,63].”
BackgroundMethodSirninger, J., Muller, C., Braag, S., Tang, Q., Yue, H., Detrisac, C., Ferkol, T., Guggino, W. B., & Flotte, T. R. (2004) · Human Gene Therapy · doi:10.1089/1043034041839262 · Cited by 69
Strategies to Modulate Immune Responses: A New Frontier for Gene Therapy
Arruda, V. R., Favaro, P., & Finn, J. D. (2009) · Molecular Therapy · doi:10.1038/mt.2009.150 · Cited by 66
Katz, M. G., Fargnoli, A. S., Williams, R. D., & Bridges, C. R. (2013) · Human Gene Therapy · doi:10.1089/hum.2013.2517 · Cited by 74
“At the same time, viral nuclear transport appears to be slow, but agents such as proteasome inhibitors can promote this movement (Duan et al., 2000).”
BackgroundSrivastava, A. (2023) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2023.05.014 · Cited by 71
Gene Therapy Progress and Prospects: Cystic fibrosis
Griesenbach, U., Ferrari, S., Geddes, D. M., & Alton, E. W. F. W. (2002) · Gene Therapy · doi:10.1038/sj.gt.3301791 · Cited by 81
Guggino, W. B., & Cebotaru, L. (2017) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2017.1347630 · Cited by 63
“The AAV2 virus that does manage to enter the cell from the apical membrane does so via a different mechanism of endocytosis, in which the viral particles are ubiquitinated and ultimately degraded in the proteasome, and therefore they do not reach the nucleus, where transduction normally occurs [42].”
BackgroundViral Vector–mediated and Cell-based Therapies for Treatment of Cystic Fibrosis
Flotte, T. R., Ng, P., Dylla, D. E., McCray, P. B., Wang, G., Kolls, J. K., & Hu, J. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300002 · Cited by 72
López-Gordo, E., Chamberlain, K., Riyad, J. M., Kohlbrenner, E., & Weber, T. (2024) · Viruses · doi:10.3390/v16030442 · Cited by 70
“…MHC class I or II, following intracellular proteasomal degradation of AAV capsids or therapeutic proteins to induce a cytotoxic immune response [217–219]. the immune responses toward the capsid, the host cells also recognize AAV DNA via Toll-like receptor 9 (TLR9) to induce innate immunity and a…”
BackgroundEfficient Whole-body Transduction with Trans-splicing Adeno-associated Viral Vectors
Ghosh, A., Yue, Y., Long, C., Bostick, B., & Duan, D. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300081 · Cited by 62
Self-citationRos, C., & Kempf, C. (2004) · Virology · doi:10.1016/j.virol.2004.04.016 · Cited by 69
“It has been shown that in cells with active proteasomes, a proportion of incoming AAV particles are ubiquitinated and degraded (Douar et al., 2001; Duan et al., 2000; Yan et al., 2002).”
BackgroundMethodInfluentialLevings, R. W., Broome, T. A., Smith, A. D., Rice, B. L., Gibbs, E. P., Myara, D. A., Hyddmark, E. V., Nasri, E., Zarezadeh, A., Levings, P. P., et al. (2018) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.142 · Cited by 71
Yan, Z., Sun, X., Feng, Z., Li, G., Fisher, J. T., Stewart, Z. A., & Engelhardt, J. F. (2015) · Human Gene Therapy · doi:10.1089/hum.2015.001 · Cited by 64
“In studies of polarized HAE, the majority of AAV2 virions were internalized after apical infection, but accumulated in the cytoplasm rather than entering the nucleus.(18,22) One obstacle to the intracellular trafficking required for productive viral transduction is the ubiquitin– proteasome pathway(18,23); transient i…”
BackgroundResultSelf-citationSendai virus-mediated CFTR gene transfer to the airway epithelium
Ferrari, S., Griesenbach, U., Iida, A., Farley, R., Wright, A. M., Zhu, J., Munkonge, F. M., Smith, S. N., You, J., Ban, H., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302991 · Cited by 63
Mitchell, A. M., & Samulski, R. J. (2013) · Journal of Virology · doi:10.1128/jvi.01826-13 · Cited by 63
“This agrees with previous results demonstrating increased nuclear localization of virus following PI treatment (6, 11, 17, 23, 26, 27) and specifically increased nucleolar localization (8).”
BackgroundResultSong, Y., Lou, H., Boyer, J. L., Limberis, M. P., Vandenberghe, L. H., Hackett, N. R., Leopold, P. L., Wilson, J. M., & Crystal, R. G. (2008) · Human Gene Therapy · doi:10.1089/hum.2008.173 · Cited by 65
“IB3 cells were treated with 40 m M N -acetyl- l -leucyl- l -leucyl- l -norleucine (LLnL; Boston Biochemical, Boston, MA), a proteasome inhibitor that enhances AAV-mediated gene expression (Duan et al. , 2000b).”
InfluentialEnhancing rAAV vector expression in the lung
Virella‐Lowell, I., Zusman, B., Foust, K., Loiler, S., Conlon, T., Song, S., Chesnut, K. A., Ferkol, T., & Flotte, T. R. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.759 · Cited by 62
“The possible causes for low gene expression in the lung with rAAV vectors include a relative paucity of receptors for AAV2 on the apical surface of airway epithelial cells, difficulties in endosomal processing and trafficking of the AAV virus to the nucleus, a tendency for the vector to persist in episome form rather…”
BackgroundHacker, U. T., Wingenfeld, L., Kofler, D. M., Schuhmann, N. K., Lutz, S., Herold, T., King, S. B. S., Gerner, F. M., Perabo, L., Rabinowitz, J., et al. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.782 · Cited by 63
“Inhibition of proteasome activity was shown to abolish this effect in endothelial cells and airway epithelia [46,47].”
BackgroundRos, C., Baltzer, C., Mani, B., & Kempf, C. (2005) · Virology · doi:10.1016/j.virol.2005.09.030 · Cited by 72
Grosse, S., Penaud-Budloo, M., Herrmann, A.-K., Börner, K., Fakhiri, J., Laketa, V., Krämer, C., Wiedtke, E., Gunkel, M., Ménard, L., et al. (2017) · Journal of Virology · doi:10.1128/jvi.01198-17 · Cited by 57
Progress in the Use of Adeno-Associated Viral Vectors for Gene Therapy
Büning, H., Braun‐Falco, M., & Hallek, M. J. (2004) · Cells Tissues Organs · doi:10.1159/000079988 · Cited by 76
“Besides that, new developments have allowed to overcome the vector size limitation through viral DNA heterodimerization [Duan et al., 2000a; Sun et al., 2000].”
BackgroundQing, K., Li, W., Zhong, L., Tan, M., Hansen, J., Weigel-Kelley, K. A., Chen, L., Yoder, M. C., & Srivastava, A. (2003) · Journal of Virology · doi:10.1128/jvi.77.4.2741-2746.2003 · Cited by 64
“These obstacles include (i) lack of optimal expression of the cellular receptor heparan sulfate proteoglycan HSPG for viral binding (43) and lack of optimal expression of the coreceptors fibroblast growth factor receptor 1 (FGFR1) and/or V 5 integrin for viral entry (35, 42), (ii) impaired endosomal processing leading…”
BackgroundJacques, S. J., Ahmed, Z., Forbes, A., Douglas, M. R., Vigenswara, V., Berry, M., & Logan, A. (2012) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2012.03.002 · Cited by 67
Jennings, K., Miyamae, T., Traister, R., Marinov, A., Katakura, S., Sowders, D., Trapnell, B., Wilson, J. M., Gao, G., & Hirsch, R. (2005) · Molecular Therapy · doi:10.1016/j.ymthe.2004.10.020 · Cited by 59
Denby, L., Nicklin, S. A., & Baker, A. H. (2005) · Gene Therapy · doi:10.1038/sj.gt.3302564 · Cited by 61
LDLR-Gene therapy for familial hypercholesterolaemia: problems, progress, and perspectives
Al-Allaf, F. A., Coutelle, C., Waddington, S. N., David, A. L., Harbottle, R. P., & Themis, M. (2010) · International Archives of Medicine · doi:10.1186/1755-7682-3-36 · Cited by 70
Gene Therapy for Cystic Fibrosis
Mueller, C., & Flotte, T. R. (2008) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-008-8080-3 · Cited by 66
Sanlioglu, S., Duan, D., & Engelhardt, J. F. (1999) · Human Gene Therapy · doi:10.1089/10430349950018661 · Cited by 60
Self-citationCheng, B., Ling, C., Dai, Y., Lu, Y., Glushakova, L. G., Gee, S. W. Y., McGoogan, K. E., Aslanidi, G. V., Park, M., Stacpoole, P. W., et al. (2012) · Gene Therapy · doi:10.1038/gt.2011.105 · Cited by 59
Fakhiri, J., Schneider, M. A., Puschhof, J., Stanifer, M., Schildgen, V., Holderbach, S., Voss, Y., El Andari, J., Schildgen, O., Boulant, S., et al. (2019) · Molecular Therapy - Methods & Clinical Development · doi:10.1016/j.omtm.2019.01.003 · Cited by 56
“Moreover, since proteasome inhibitors mostly increase transduction from the apical side,(34) their use may have particularly boosted AAV2, which normally prefers the basolateral side.(36)”
BackgroundSelf-citationEndocytic processing of adeno-associated virus type 8 vectors for transduction of target cells
Liu, Y., Joo, K.-I., & Wang, P. (2012) · Gene Therapy · doi:10.1038/gt.2012.41 · Cited by 59
A versatile toolkit for overcoming AAV immunity
Li, X., Wei, X., Lin, J., & Ou, L. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.991832 · Cited by 57
“After entry into cells, AAV cells can be ubiquitinated for degradation in proteasomes (91), generating increased amount of antigens for immune activation.”
BackgroundMaterials promoting viral gene delivery
Kaygisiz, K., & Synatschke, C. V. (2020) · Biomaterials Science · doi:10.1039/d0bm01367f · Cited by 59
Herzog, R. W. (2015) · Frontiers in Bioscience · doi:10.2741/4324 · Cited by 55
“VIII using these oversized AAV vectors (74, 75, 278-280).”
MethodUhrig, S., Coutelle, O., Wiehe, T., Perabò, L., Hallek, M. J., & Büning, H. (2011) · Gene Therapy · doi:10.1038/gt.2011.78 · Cited by 60
Viscoelastic Gel Formulations Enhance Airway Epithelial Gene Transfer with Viral Vectors
Sinn, P. L., Shah, A. J., Donovan, M. D., & McCray, P. B. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2004-0410oc · Cited by 63
Fischer, A. C., Smith, C. I., Cebotaru, L., Zhang, X., Askin, F. B., Wright, J., Guggino, S. E., Adams, R. J., Flotte, T., & Guggino, W. B. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300059 · Cited by 55
Zhong, L., Li, W., Yang, Z., Qing, K., Tan, M., Hansen, J., Li, Y., Chen, L., Chan, R. J., Bischof, D., et al. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.1207 · Cited by 59
Xu, Z., Yue, Y., Lai, Y., Ye, C., Qiu, J., Pintel, D. J., & Duan, D. (2004) · Human Gene Therapy · doi:10.1089/hum.2004.15.896 · Cited by 55
“Histochemical staining for heat-resistant AP and nuclear-localized lacZ was performed at 37¡C for 10 min and 2 hr, respectively, in 8 m m cryosections according to previously published protocols (Duan et al ., 2000b, 2001b).”
Self-citationGene therapy for cystic fibrosis: Challenges and prospects
Sui, H., Xu, X., Su, Y., Gong, Z., Yao, M., Liu, X., Zhang, T., Jiang, Z., Bai, T., Wang, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.1015926 · Cited by 60
“Subsequent research on vector intracellular trafficking revealed that impaired vector nuclear transport was the rate-limiting step in rAAV productive transduction in polarized airway epithelium (Duan et al., 2000).”
BackgroundWang, L.-N., Wang, Y., Lu, Y., Yin, Z.-F., Zhang, Y.-H., Aslanidi, G., Srivastava, A., Ling, C., & Ling, C. (2014) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(14)60003-0 · Cited by 54
Copreni, E., Penzo, M., Carrabino, S., & Conese, M. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302372 · Cited by 58
Parvoviruses: Structure and Infection
Halder, S., Ng, R., & Agbandje-McKenna, M. (2012) · Future Virology · doi:10.2217/fvl.12.12 · Cited by 54
Ferrari, S., Uta Griesenbach, D., Shiraki-Iida, T., Shu, T., Hironaka, T., Hou, X., Williams, J. L., Zhu, J., Jeffery, P. K., Geddes, D. M., et al. (2004) · Gene Therapy · doi:10.1038/sj.gt.3302334 · Cited by 53
The roles of traditional Chinese medicine in gene therapy
Ling, C., Wang, L., Wang, Y., Zhang, Y., Yin, Z.-F., Wang, M., & Ling, C. (2014) · Journal of Chinese Integrative Medicine · doi:10.1016/s2095-4964(14)60019-4 · Cited by 54
Wang, M., Sun, J., Crosby, A., Woodard, K., Hirsch, M. L., Samulski, R. J., & Li, C. (2017) · Gene Therapy · doi:10.1038/gt.2016.75 · Cited by 51
“method to enhance AAV vector transduction relies on altered cellular physiology via pharmacological agents(12-22).”
MethodMechanisms of AAV transduction in glaucoma‐associated human trabecular meshwork cells
Borrás, T., Xue, W., Choi, V. W., Bartlett, J. S., Li, G., Samulski, R. J., & Chisolm, S. S. (2006) · The Journal of Gene Medicine · doi:10.1002/jgm.886 · Cited by 51
“Other studies reported that inhibition of proteosome activity resulted in increased transduction probably by favoring trafficking of rAAV to the nucleus [16,17].”
BackgroundJohnson, L. G., Vanhook, M. K., Coyne, C. B., Haykal-Coates, N., & Gavett, S. H. (2003) · Human Gene Therapy · doi:10.1089/104303403765255138 · Cited by 54
Innate immune sensing of adeno-associated virus vectors
Cao, D., Byrne, B. J., de Jong, Y. P., Terhorst, C., Duan, D., Herzog, R. W., & Kumar, S. R. P. (2024) · Human Gene Therapy · doi:10.1089/hum.2024.040 · Cited by 50
Self-citationActivation of the Cellular Unfolded Protein Response by Recombinant Adeno-Associated Virus Vectors
Balakrishnan, B., Sen, D., Hareendran, S., Roshini, V., David, S., Srivastava, A., & Jayandharan, G. R. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053845 · Cited by 50
“Remarkably, while the inhibition of ER stress by proteasome inhibitors [14] or in cellular models [15] has been shown to improve the transduction of AAV, conversely, the role of AAV vector load induced stress on ER compartment and its ensuing signalling events are not known.”
BackgroundZhang, L. N., Karp, P., Gerard, C. J., Pastor, E., Laux, D., Munson, K., Yan, Z., Liu, X., Godwin, S., Thomas, C. P., et al. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.08.009 · Cited by 50
Self-citationJohnson, J. S., Gentzsch, M., Zhang, L., Ribeiro, C. M. P., Kantor, B., Kafri, T., Pickles, R. J., & Samulski, R. J. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002053 · Cited by 48
“Likewise, pharmacological inhibition of the proteasome results in a potent increase in AAV infection efficiency in a celland serotype-specific manner [28,64], although the mechanisms responsible are not completely understood.”
InfluentialGalen, B. T., Cheshenko, N., Tuyama, A. C., Ramratnam, B., & Herold, B. C. (2006) · Journal of Virology · doi:10.1128/jvi.01503-06 · Cited by 49
“Studies suggest that polarized differences in endosomal processing and nuclear trafficking of internalized virus may also be important (11).”
BackgroundRecombinant adeno-associated virus vectors for gene therapy
Conlon, T. J., & Flotte, T. R. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.7.1093 · Cited by 49
“In addition, targeting may be useful in non-permissive or poorly permissive cells, such as apical lung epithelial cells [36], pancreatic beta cells and vascular endothelial cells.”
BackgroundInfluentialNicolson, S. C., Li, C., Hirsch, M. L., Setola, V., & Samulski, R. J. (2016) · Journal of Virology · doi:10.1128/jvi.02953-15 · Cited by 48
The curious case of AAV immunology
Keeler, A. M., Zhan, W., Ram, S., Fitzgerald, K. A., & Gao, G. (2025) · Molecular Therapy · doi:10.1016/j.ymthe.2025.03.037 · Cited by 52
Liu, X., Yan, Z., Luo, M., & Engelhardt, J. F. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2005-0189oc · Cited by 47
“Given that both serotypes appear to bind with similar efficiencies to the apical membrane of mouse (Figure 5B) and human (16) airway epithelia, we conclude that proteasomedependent barriers to rAAV2 transduction are enhanced in mouse as compared with human airway epithelia.”
BackgroundMethodInfluentialSelf-citationUnique Biologic Properties of Recombinant AAV1 Transduction in Polarized Human Airway Epithelia
Yan, Z., Lei-Butters, D. C. M., Liu, X., Zhang, Y., Zhang, L., Luo, M., Zak, R., & Engelhardt, J. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604099200 · Cited by 48
Self-citationZhong, L., Qing, K., Si, Y., Chen, L., Tan, M., & Srivastava, A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310548200 · Cited by 49
Comparative biology of rAAV transduction in ferret, pig and human airway epithelia
Liu, X., Luo, M., Guo, C., Yan, Z., Wang, Y., & Engelhardt, J. F. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303014 · Cited by 47
Self-citationGhosh, A., Yue, Y., Shin, J.-H., & Duan, D. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.058 · Cited by 44
“In situ expression was determined by histochemical staining of 8-mm cryosections as described previously (Duan et al., 2000).”
MethodSelf-citationIn Utero AAV-Mediated Gene Transfer to Rabbit Pulmonary Epithelium
Boyle, M., Enke, R. A., Adams, R. J., Guggino, W. B., & Zeitlin, P. L. (2001) · Molecular Therapy · doi:10.1006/mthe.2001.0428 · Cited by 45
“While some of the observed differences in expression may be due to promoter influences and tissue-specific ubiquitination of viral capsid proteins, the differences also provide support for the observation of a significantly lower transduction efficiency of rAAV at the apical surface of airway epithelial cells [1,16,21…”
ResultGene therapy: Recombinant adeno-associated virus vectors
Smith-Arica, J. R., & Bartlett, J. S. (2001) · Current Cardiology Reports · doi:10.1007/s11886-001-0009-x · Cited by 47
“Indeed, a recent study looking at the infection of polarized airway epithelial cells suggests that one reason for the low AAV transduction efficiency in these cells is aberrant endosomal processing and nuclear trafficking of the viral particles [ 41 ].”
BackgroundKeiser, N. W., Yan, Z., Zhang, Y., Lei-Butters, D. C. M., & Engelhardt, J. F. (2011) · Human Gene Therapy · doi:10.1089/hum.2011.044 · Cited by 40
“The intracellular trafficking of rAAV2/2 has been shown to be quite slow (Duan et al. , 2000; Hansen et al. , 2000), and enhancement of this process with proteasome inhibitors can facilitate viral movement to the nucleus and enhance transduction (Duan et al. , 2000; Yan et al. , 2002, 2004).”
Self-citationZhong, L., Chen, L., Li, Y., Qing, K., Weigel-Kelley, K. A., Chan, R. J., Yoder, M. C., & Srivastava, A. (2004) · Molecular Therapy · doi:10.1016/j.ymthe.2004.07.018 · Cited by 45
Adeno-Associated Virus Expresses Transgenes in Hair Follicles and Epidermis
Hengge, U. R., & Mirmohammadsadegh, A. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0118 · Cited by 51
Recombinant Adeno-Associated Virus Utilizes Cell-Specific Infectious Entry Mechanisms
Weinberg, M. S., Nicolson, S., Bhatt, A. P., McLendon, M., Li, C., & Samulski, R. J. (2014) · Journal of Virology · doi:10.1128/jvi.01971-14 · Cited by 39
“ficking ubiquitination and/or proteasomal degradation of rAAV virions (14, 15), affecting nuclear localization signals on the viral”
BackgroundBorok, Z., Harboe-Schmidt, J. E., Brody, S. L., You, Y., Zhou, B., Li, X., Cannon, P. M., Kim, K., Crandall, E. D., & Kasahara, N. (2001) · Journal of Virology · doi:10.1128/jvi.75.23.11747-11754.2001 · Cited by 43
“(13) recently observed that, in human airway epi-”
BackgroundLiu, X., Yan, Z., Luo, M., Zak, R., Li, Z., Driskell, R. R., Huang, Y., Tran, N., & Engelhardt, J. F. (2004) · Journal of Virology · doi:10.1128/jvi.78.8.4165-4175.2004 · Cited by 41
“Intercellular trafficking of AAV has been shown to play a critical role in rAAV gene transduction in both AAV-permissive and -nonpermissive cells (19, 23, 24).”
BackgroundSelf-citationAdeno-Associated Virus Vectors and Stem Cells: Friends or Foes?
Brown, N. J., Song, L., Rao, K. N., & Hirsch, M. L. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.038 · Cited by 43
“Once in the cytoplasm, vectors accumulate perinuclearly by an unknown mechanism likely involving the cytoskeleton.(99) Studies have shown that each of these steps can have a large impact on vector transduction efficiency.”
BackgroundMitchell, A. M., Li, C., & Samulski, R. J. (2013) · Journal of Virology · doi:10.1128/jvi.03443-12 · Cited by 41
Yan, Z., Lei-Butters, D. C. M., Zhang, Y., Zak, R., & Engelhardt, J. F. (2007) · Human Gene Therapy · doi:10.1089/hum.2006.128 · Cited by 41
Self-citationGoodrich, L. R., Choi, V. W., Carbone, B. A. D., McIlwraith, C. W., & Samulski, R. J. (2009) · Human Gene Therapy · doi:10.1089/hum.2009.030 · Cited by 41
“This can likely be attributed to species-specific differences in tissue tropism of AAV sero-types (Duan et al. , 2000; Sanlioglu et al. , 2001), and stresses the need to test various AAV serotypes in the species of interest before testing therapeutic transgenes.”
Human Bocavirus 1 Is a Novel Helper for Adeno-associated Virus Replication
Wang, Z., Deng, X., Zou, W., Engelhardt, J. F., Yan, Z., & Qiu, J. (2017) · Journal of Virology · doi:10.1128/jvi.00710-17 · Cited by 42
Self-citationSłyk, Ż., Stachowiak, N., & Małecki, M. (2024) · Biomedicines · doi:10.3390/biomedicines12071523 · Cited by 44
Han, Z., Conley, S. M., & Naash, M. I. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6916 · Cited by 40
Yan, Z., Feng, Z., Sun, X., Zhang, Y., Zou, W., Wang, Z., Jensen-Cody, C. W., Liang, B., Park, S.-Y., Qiu, J., et al. (2017) · Human Gene Therapy · doi:10.1089/hum.2017.060 · Cited by 40
Self-citationCorrection of Airway Stem Cells: Genome Editing Approaches for the Treatment of Cystic Fibrosis
King, N. E., Suzuki, S., Barillà, C., Hawkins, F. J., Randell, S. H., Reynolds, S. D., Stripp, B. R., & Davis, B. R. (2020) · Human Gene Therapy · doi:10.1089/hum.2020.160 · Cited by 43
Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions
White, K., Büning, H., Kritz, A., Janicki, H., McVey, J. H., Perabò, L., Murphy, G., Odenthal, M., Work, L. M., Hallek, M. J., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3303077 · Cited by 45
Jayandharan, G. R., Zhong, L., Sack, B. K., Rivers, A. E., Li, M., Li, B., Herzog, R. W., & Srivastava, A. (2010) · Human Gene Therapy · doi:10.1089/hum.2009.100 · Cited by 38
“…coreceptor-mediated viral binding and entry (Summerford and Samulski, 1998; Qing et al. , 1999; Summerford et al. , 1999), intracellular trafficking (Duan et al. , 1999, 2000; Bartlett et al. , 2000; Hansen et al. , 2000, 2001a), nuclear transport, uncoating (Duan et al. , 1999; Bartlett et al.…”
Flotte, T. R., Schwiebert, E. M., Zeitlin, P. L., Carter, B. J., & Guggino, W. B. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.921 · Cited by 37
“It has been reported that vector DNA administered at the apical surface of airway epithelial cells may be trafficked to an extranuclear compartment, but enter the nucleus later if appropriate stimuli are provided (Duan et al., 2000; Yan et al., 2004).”
BackgroundDual-AAV delivery of large gene sequences to the inner ear
Reisinger, E. (2020) · Hearing Research · doi:10.1016/j.heares.2019.107857 · Cited by 37
Wang, Y., Ling, C., Song, L., Wang, L., Aslanidi, G. V., Tan, M., Ling, C., & Srivastava, A. (2012) · Human Gene Therapy Methods · doi:10.1089/hgtb.2012.090 · Cited by 37
“It is now well accepted that the ubiquitin–proteasome pathway plays an essential role in AAV intracellular traf-ficking (Duan et al. , 2000; Douar et al. , 2001; Yan et al. , 2002; Cheng et al. , 2012).”
Comparison of gene expression after intraperitoneal delivery of AAV2 or AAV5 in utero
Lipshutz, G. S., Titre, D., Brindle, M. E., Bisconte, A. R., Contag, C. H., & Gaensler, K. M. L. (2003) · Molecular Therapy · doi:10.1016/s1525-0016(03)00132-1 · Cited by 37
Metadata
- Authors
- Duan, D., Yue, Y., Yan, Z., Yang, J., & Engelhardt, J. F.
- Affiliations
- University of Iowa (US)
- Corresponding author
- Engelhardt, John F.
- Venue
- Journal of Clinical Investigation
- Published
- 2000-06-01
- Volume
- 105
- Issue
- 11
- Pages
- 1573-1587
- ISSN
- 0021-9738 (ISSN-L)
- PMC
- PMC300848
- OpenAlex
- W1970138286
- Cited by
- 391
- References
- 45
- Citations by year
- 2026: 4 · 2025: 10 · 2024: 10 · 2023: 12 · 2022: 8 · 2021: 5 · 2020: 9 · 2019: 17 · 2018: 6 · 2017: 9 · 2016: 4 · 2015: 11 · 2014: 10 · 2013: 18 · 2012: 18
- FWCI
- 13.93
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Clinical Investigation (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (DK54759)
- National Heart, Lung, and Blood Institute (R01HL058340)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK54759, P30DK054759)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA Interference and Gene Delivery
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
- Keywords
- adeno-associated virus type 2, airway epithelium, endosomal processing, proteasome inhibitors, ubiquitin ligase inhibitors, nuclear trafficking, pulmonary gene therapy, cystic fibrosis
- MeSH terms
- Dependovirus, Animals, Bronchi, Capsid, Cells, Cultured, Cysteine Endopeptidases, Egtazic Acid, Epithelial Cells, Humans, Lung, Mice, Inbred BALB C, Multienzyme Complexes, Endosomes, Ubiquitins, Genetic Therapy, Cell Polarity, Gene Transfer Techniques, Proteasome Endopeptidase Complex, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.